Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas

Summary

In vitro and in vivo antitumor effects of ketoconazole (KTZ), trifluoperazine (TFP), and combinations of both drugs were examined in cell lines established from radiation leukemia virus (RadLV)-induced T-cell lymphomas. KTZ inhibited [3H]-thymidine incorporation in the tumor cells in vitro; 50% inhibition of DNA synthesis was observed at concentrations of 4–7 μg/ml. [3H]-thymidine uptake in bone-marrow and spleen cells prepared from healthy mice was also inhibited by KTZ, but 50% inhibition was observed only at a concentration of 50 μg/ml. Stimulation of spleen cells with concanavalin A led to an increase in their sensitivity to the inhibition of DNA synthesis by KTZ. The tumor-cell lines varied in their sensitivity to the inhibition of DNA synthesis by TFP, and the effects of TFP on DNA synthesis in bone-marrow and spleen cells were similar to those observed in the tumor cells. Synergistic, additive, or less than additive effects of the drug combinations on the inhibition of DNA synthesis in vitro were observed both in tumor cells and in bone-marrow cells. In vivo experiments were conducted on groups of C57BL/6 (B6) mice that were inoculated s.c. with tumor cells and then treated with i.p. injections of KTZ, TFP or both. Control groups were injected with phosphate-buffered saline (PBS). Each of the drugs alone as well as their combinations caused a significant delay in the appearance of palpable tumors, a decrease in tumor size, and a marked prolongation of survival. The concentrations of the drugs used in in vivo experiments did not affect the WBC counts in the peripheral blood of healthy mice. KTZ is currently used for the treatment of prostatic cancer because of its inhibitory effect on testosterone biosynthesis. The results of the present study indicate the hormone-independent chemotherapeutic potential of KTZ, TFP, and combinations of the two drugs.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Baldessarini RJ (1980) Drugs for treatment of psychiatric disorders. In: Goodman LS, Gilman A, Gilman AG (eds) The pharmacological basis of therapeutics, tth edn. MacMillan, London, pp 391–447

    Google Scholar 

  2. 2.

    Ben David Y, Yefenof E, Kotler M (1987) Clonal analysis of radiation leukemia virus-induced leukemic and preleukemic cells. Cancer Res 47:6590–6594

    Google Scholar 

  3. 3.

    Ben Gigi G, Polacheck I, Eilam Y (1988) In vitro synergistic activity of ketoconazole with trifluoperazine and with chlorpromazine against medical important yeasts. Chemotherapy 34:96–100

    Google Scholar 

  4. 4.

    Borgers M (1985) Antifungal azole derivatives. In: Greenwood D, O'Grady F (eds) The scientific basis of antimicrobial chemotherapy. Cambridge University Press, Cambridge, pp 133–153

    Google Scholar 

  5. 5.

    Borsa J, Einspenner M, Sargent MD, Hickie RA (1986) Selective cytotoxicity of calmidazolium and trifluoperazine for cycling versus noncycling C3H10T1/2 cells in vitro. Cancer Res 46:133–136

    Google Scholar 

  6. 6.

    Bukowski KM, Murthy S, Budd GT, Purvis J, Ganapathi R (1986) Phase I/II trial of doxorubicin (DOX) and trifluoperazine (TFP) in patients with clinical dexuribin resistance. Proc Am Assoc Cancer Res 27:208

    Google Scholar 

  7. 7.

    Chafouleas JG, Pardue RL, Brinkley BR, Dedman JR, Means AR (1981) Regulation of intracellular levels of calmodulin and tubulin in normal and transformed cells. Proc Natl Acad Sci USA 78: 996–1000

    Google Scholar 

  8. 8.

    Chafouleas JG, Bolton WE, Hikaka H, Boyd AE, Means AR (1982) Calmodulin and the cell cycle: involvement in regulation of cell cycle progression. Cell 28:41–50

    Google Scholar 

  9. 9.

    Contreras P, Auristella R (1985) Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet II: 151–152

    Google Scholar 

  10. 10.

    Contreras P, Altieri E, Liberman C, Gac A, Rojas A, Ibarra A, Ravanal M, Seron-Ferre M (1985) Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure. J Clin Endocrinol Metal 60:21–28

    Google Scholar 

  11. 11.

    De Felice R, Johnson DC, Golgiani JW (1981) Gynecomastia with ketoconazole. Antimicrob Agents Chemother 19:1073–1074

    Google Scholar 

  12. 12.

    DiMattina M, Loriaux DL, Maronian N, Albertson BD, Ashley H (1988) Ketoconazole inhibits multiple steroidogenic enzymes involved in androgen biosynthesis in the human ovary. Fertil Steril 49: 62–65

    Google Scholar 

  13. 13.

    Eilam Y, Chernichovski D (1988) Low concentrations of trifluoperazine arrest cell division cycle ofSaccharomyces cerevisiae at two specific stages. J Gen Microbiol 134:1063–1069

    Google Scholar 

  14. 14.

    Feldman LD (1986) Ketoconazole for male metastatic breast cancer. Ann Intern Med 104:123–124

    Google Scholar 

  15. 15.

    Ganapathi R, Grabowski D (1988) Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance. Biochem Pharmacol 37:185–193

    Google Scholar 

  16. 16.

    Ganapathi R, Schmidt H, Grabowski D, Melia M, Ratcliff N (1988) Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance. Br J Cancer 58:335–340

    Google Scholar 

  17. 17.

    Grief F, Soroff HS, Albers KM, Taichman LB (1989) Effect of trifluoperazine, a calmodulin antagonist, on the growth of normal and malignant epidermal keratinocytes in culture. Eur J Cancer Clin Oncol 25:19–26

    Google Scholar 

  18. 18.

    Hackney JF, Schwartz DA (1988) Ketoconazole inhibition and glucocorticoid action in the human lymphoblastic leukemia cell line CEM-C7. J Steroid Biochem 29:15–19

    Google Scholar 

  19. 19.

    Hait WN, Grais L, Benz C, Cadman EC (1985) Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melitin. Cancer Chemother Pharmacol 14:202–205

    Google Scholar 

  20. 20.

    Harris AL, Cantwell BMJ, Dowsett M (1988) High doses of ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer 58:493–496

    Google Scholar 

  21. 21.

    Hickie RA, Wei J-W, Blyth LM, Wong DYW (1983) Cations and calmodulin in normal and neoplastic cell growth. Can J Biochem Cell Biol 61:934–941

    Google Scholar 

  22. 22.

    Kraemer FB, Pont A (1986) Inhibition of cholesterol synthesis by ketoconazole. Am J Med 80:616–622

    Google Scholar 

  23. 23.

    Lambert A, Mitchell R, Robertson WR (1986) The effect of ketoconazole on adrenal and testicular steroidogenesis in vitro. Biochem Pharmacol 35:3999–4004

    Google Scholar 

  24. 24.

    Lehnert S (1986) In vivo toxicity of phenothiazines to cells of a transplantable tumor. Cancer Chemother Pharmacol 16:296–272

    Google Scholar 

  25. 25.

    Levin RM, Weiss B (1976) Mechanism by which psychotropic drugs inhibit adenosine cyclic 3′5′-monophosphate phosphodiesterase of brain. Mol Pharmacol 12:581–589

    Google Scholar 

  26. 26.

    Loose DS, Kan PB, Hirost MA, Marcus RA (1983) Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P-450-dependent enzymes. J Clin Invest 71:1495–1499

    Google Scholar 

  27. 27.

    Means AR, Rasmussen CD (1988) Calcium, calmodulin and cell proliferation. Cell Calcium 9:313–319

    Google Scholar 

  28. 28.

    Miller RL, Bukowski RW, Budd GT, Purvis J, Weick JK, Shepard K, Midha KK, Ganapathi R (1988) Clinical modulation of doxorubicin resistance by the calmodulin inhibitor, trifluoperazine; a phase I/II trial. J Clin Oncol 6:880–888

    Google Scholar 

  29. 29.

    Nardone PA, Slotman GJ, Vezeridis MP (1988) Ketoconazole: a thromboxane synthetase and 5-lipoxygenase inhibitor with antimetastatic activity in B16-F10 melanoma. J Surg Res 44:425–429

    Google Scholar 

  30. 30.

    Pont A (1987) Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol 137: 902–904

    Google Scholar 

  31. 31.

    Prozialek WE, Weiss B (1982) Inhibition of calmodulin by phenothiazines and related drugs: structure-activity relationships. J Pharmacol Exp Ther 222:509–516

    Google Scholar 

  32. 32.

    Rasmussen CD, Means AR (1989) Calmodulin is required for cell cycle progression during G1 and mitosis. EMBO J 8:73–82

    Google Scholar 

  33. 33.

    Rochlitz CF, Damon LE, Russi MB, Geddes A, Cadman EC (1988) Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 21:319–322

    Google Scholar 

  34. 34.

    Sasaki Y, Hidaka H (1982) Calmodulin and cell proliferation. Biophys Biochem Res Commun 104:451–456

    Google Scholar 

  35. 35.

    Stewart DJ, Evans WK (1989) Non chemotherapeutic agents that potentiate chemotherapy efficacy. Cancer Treat Rev 16:1–40

    Google Scholar 

  36. 36.

    Trachtenberg J (1989) Ketoconazole therapy in advanced prostatic cancer. J Urol 132:61–63

    Google Scholar 

  37. 37.

    Van den Bossche H, Willemsens G, Cools W, Cornelissen F, Lauwers WF, Van Cutsen JM (1980) In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol biosynthesis. Antimicrob Agents Chemother 17:922–928

    Google Scholar 

  38. 38.

    Wamplet G (1983) The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs 25 [Suppl 1]:35–51

    Google Scholar 

  39. 39.

    Wei JW, Hickie RA, Klaassen DJ (1983) Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7 and W-13. Cancer Chemother Pharmacol 11:86–90

    Google Scholar 

  40. 40.

    Williams G (1984) Ketoconazole for prostate cancer. Lancet II:696

    Google Scholar 

  41. 41.

    Yefenof E, Feinman R, Kedar E (1985) Antigen nonspecific activities in culture supernatant of ovalbumin-specific cloned helper T lymphoma. Immunobiology 169:520–531

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Y. Eilam.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Naftalovich, S., Yefenof, E. & Eilam, Y. Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas. Cancer Chemother. Pharmacol. 28, 384–390 (1991). https://doi.org/10.1007/BF00685694

Download citation

Keywords

  • Testosterone
  • Thymidine
  • Ketoconazole
  • Antitumor Effect
  • Spleen Cell